N-tert-butyl-α-Phenylnitrone

Research use only, not for human use.

N-tert-butyl-α-Phenylnitrone inhibits COX2 catalytic activity.

N-tert-butyl-α-Phenylnitrone inhibits COX2 catalytic activity. N-tert-butyl-α-Phenylnitrone possesses potent reactive oxygen species scavenging, anti-inflammatory, neuroprotective, anti-aging, and anti-diabetic activities, and can penetrate the blood-brain barrier.(In Vitro):Treatment of 25-100 μM N-tert-butyl-α-Phenylnitrone significantly reduces 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-butyl-α-Phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis, inhibiting AAPH-induced ERK/MAPK pathway activation. (In Vivo):In C57Bl/6 mice induced by lipopolysaccharide (LPS), intraperitoneal injection of 100 mg/kg N-tert-butyl-α-Phenylnitrone twice a day (on gestational day 8) abolishes LPS-induced lipid peroxidation, nitrate tyrosine residue levels and GSH depletion, and reduces the incidence of external malformations.

N-tert-Butyl-α-phenylnitrone (PBN) (25-100 μM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research.

N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations. Animal Model:C57Bl/6 mice induced by lipopolysaccharide (LPS) Dosage:100 mg/kg Administration:Intraperitoneal injection; twice a day (on gestational day 8)Result:Abolished LPS-induced lipid peroxidation, nitrotyrosine residues, and GSH depletion.

(Z)-N-benzylidene-2-Methylpropan-2-aMine oxide

Immunology/Inflammation

ROS

——

——

——

3376-24-7

177.247

C11H15NO

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (564.21 mM)

CC(C)(C)[N+](\[O-])=C\c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years